Narasimhan was appointed on April 14 by the Anthropic Long-Term Benefit Trust, the independent body whose members hold no equity in Anthropic and exist solely to elect board directors aligned with the company’s public benefit mission.With his appointment, Trust-selected directors now hold a majority of seats on the seven-person board, a governance threshold written into Anthropic’s founding documents but not crossed until now.The appointment lands as Anthropic weighs an IPO at a reported $380 billion valuation and deepens its push into healthcare through Claude for Life Sciences and Claude for Healthcare.